Related Experiment Video

Updated: Aug 30, 2026

A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level
05:35

A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level

Published on: January 19, 2024

Anemia in the treatment of hepatitis C virus infection

Mark S Sulkowski1

  • 1Center for Viral Hepatitis, Johns Hopkins University, Baltimore, Maryland 21205, USA. msulkows@jhmi.edu

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|October 29, 2003
PubMed

Insights

Hepatitis C virus (HCV) coinfection with HIV accelerates liver disease. Epoetin alfa helps manage anemia during treatment, potentially improving outcomes for coinfected patients.

Area of Science:

  • Hepatology
  • Virology
  • Clinical Medicine

Background:

  • Hepatitis C virus (HCV) infection is a global health concern.
  • HCV/HIV coinfection leads to faster liver disease progression and higher mortality compared to HIV alone.
  • Standard HCV treatment (interferon and ribavirin) can cause severe anemia, especially in coinfected individuals.

Purpose of the Study:

  • To evaluate the efficacy of epoetin alfa in managing anemia associated with interferon-ribavirin therapy in HCV-infected patients.
  • To assess the impact of epoetin alfa on maintaining ribavirin dosage and adherence.
  • To explore the potential effect of epoetin alfa on sustained virologic response (SVR) rates in HCV/HIV coinfected patients.

Main Methods:

  • Retrospective analysis of HCV-infected patients undergoing interferon-ribavirin therapy.
  • Comparison of patients receiving epoetin alfa for anemia versus those with ribavirin dose reduction.
  • Monitoring of hemoglobin levels, ribavirin dosage, adherence, and SVR rates.

Main Results:

  • Epoetin alfa significantly increased hemoglobin levels and allowed for higher ribavirin doses compared to dose reduction alone.
  • Patients treated with epoetin alfa maintained better adherence to HCV therapy.
  • Higher ribavirin doses and adherence are linked to improved SVR rates.

Conclusions:

  • Epoetin alfa is effective in managing interferon-ribavirin-induced anemia in HCV-infected patients.
  • Maintaining optimal ribavirin doses and adherence through epoetin alfa may improve treatment outcomes, including SVR.
  • Epoetin alfa represents a valuable therapeutic option for HCV/HIV coinfected patients experiencing treatment-related anemia.

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...